DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde


Baselga J, Dent SF, Cortés J. et al.
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

J Clin Oncol 2018;
36 (Suppl.) Abstr.. LBA1006

Download Bibliographical Data

Search in: